USA: Researchers have found in a recent observational study that patients with generalized pustular psoriasis (GPP) face a ...

Mark G. Lebwohl, MD, gives an overview of generalized pustular psoriasis (GPP) and explains how it differs from the more common plaque psoriasis.

But we know with generalized pustular psoriasis [GPP], IL-36 plays a unique role. Talk to us a little bit about what’s different in IL-36 and why is it uniquely positioned for GPP patients.

Boehringer Ingelheim, one of the industry leading investors in research and development in innovative life expectancy ...

LEO is claiming global commercial rights to Spevigo for GPP, but will also collaborate with Boehringer on potential follow-up ...

Boehringer Ingelheim and LEO Pharma enter partnership to commercialize and further develop SPEVIGO® (spesolimab) ...

AAD > Psoriasis. IL-36 And Generalized Pustular Psoriasis: L'chaim! – An American Academy of Dermatology Reading Room selection March 25, 2022 Warren R. Heymann, MD, FAAD ...

LEO has plans for Spevigo beyond generalised pustular psoriasis as it looks to boost its dermatological pipeline.

Three-quarters of patients with generalized pustular psoriasis demonstrated response to treatment with an interleukin-36-targeted therapy as early as 4 weeks, according to a study.“Generalized ...

RIDGEFIELD, Conn., March 7, 2025 /PRNewswire/ -- Today, Boehringer Ingelheim announced new analyses to be presented at the American Academy of Dermatology (AAD) annual meeting in Orlando that ...

Boehringer Ingelheim set to receive EUR 90 million as upfront payment, along with milestone payments and tiered royalties.

Boehringer Ingelheim & LEO Pharma partner to commercialize and further develop Spevigo: Ingelheim, Germany Wednesday, July 16, 2025, 15:00 Hrs [IST] Boehringer Ingelheim, a biopha ...